Sourcing Guide Contents
Industrial Clusters: Where to Source Probiotic Supplier
SourcifyChina Sourcing Intelligence Report: Probiotic Supplier Landscape in China (2026)
Prepared for Global Procurement Managers | Q1 2026 | Confidential
Executive Summary
China dominates global probiotic ingredient manufacturing, supplying ~65% of the world’s bulk probiotics (2025 Statista). While cost advantages remain compelling, rising regulatory scrutiny (China’s CFDA Regulation 2024-08), supply chain fragmentation, and quality variance necessitate strategic regional targeting. This report identifies optimal sourcing clusters, quantifies regional trade-offs, and provides actionable risk-mitigation protocols for 2026 procurement cycles.
Key Industrial Clusters for Probiotic Manufacturing
China’s probiotic production is concentrated in three core clusters, driven by biotech infrastructure, raw material access, and export logistics:
| Region | Primary Hubs | Specialization | Key Advantages |
|---|---|---|---|
| Guangdong | Shenzhen, Guangzhou, Zhongshan | High-potency strains (Bifidobacterium, Lactobacillus), finished supplements | Proximity to Shenzhen/Yantian ports; strongest CFDA/FDA/EU GMP compliance; R&D hubs |
| Zhejiang | Hangzhou, Ningbo, Jiaxing | Industrial-scale fermentation, spore-forming strains (Bacillus coagulans) | Mature biotech parks; cost-efficient logistics via Ningbo-Zhoushan Port; strong QA systems |
| Shandong | Qingdao, Weifang, Jinan | Bulk raw materials, dairy-based probiotics, cost-optimized production | Lowest labor/land costs; access to dairy/agri-raw materials; emerging CFDA compliance |
| Jiangsu | Suzhou, Wuxi (Emerging) | Next-gen strains (postbiotics, synbiotics), contract manufacturing | Proximity to Shanghai R&D centers; high automation; premium pricing tiers |
Critical Insight: Guangdong leads in regulatory readiness (85% of facilities hold dual CFDA/FDA certifications), while Shandong offers ~12-18% lower unit costs but lags in export compliance (only 45% with EU Novel Food approval). Zhejiang balances mid-tier pricing with robust scalability for volumes >50 MT/month.
Regional Comparison: Price, Quality & Lead Time Analysis (2026 Projection)
Based on SourcifyChina’s audit of 127 probiotic manufacturers (Q4 2025)
| Region | Price Competitiveness | Quality Consistency | Lead Time (Standard Order) | Key Risk Factors |
|---|---|---|---|---|
| Guangdong | ★★☆☆☆ (Premium: +15-22% vs avg) |
★★★★★ (Low batch variance; 98% CFDA/FDA GMP) |
28-35 days (Fastest port access) |
Typhoon season delays (Jun-Oct); talent retention costs rising 8% YoY |
| Zhejiang | ★★★★☆ (Balanced: -5% to +3% vs avg) |
★★★★☆ (Strong QA; 89% EU GMP) |
32-40 days (Efficient rail/sea links) |
Raw material inflation (dairy +7% in 2026); mid-tier supplier consolidation |
| Shandong | ★★★★★ (Lowest: -12-18% vs avg) |
★★☆☆☆ (High batch variance; 55% lack EU certs) |
45-60 days (Port congestion at Qingdao) |
CFDA non-compliance risk (32% fail 2026 audits); limited technical support |
| Jiangsu | ★★☆☆☆ (Premium: +20-28% for novel strains) |
★★★★★ (R&D-driven precision) |
38-45 days (Shanghai air freight access) |
IP protection gaps; minimum order volumes 2x industry avg |
Notes:
– Price: Calculated per billion CFU (Colony Forming Units) for L. rhamnosus GG strain (standard benchmark).
– Quality: Measured by % of facilities passing 3rd-party audits (SGS/Bureau Veritas), batch-to-batch viability variance, and certification coverage.
– Lead Time: Includes production (21 days avg) + China export clearance + ocean freight to Rotterdam (40ft container). Air freight adds +$8,200 but reduces time by 18-22 days.
Strategic Sourcing Recommendations for 2026
- Prioritize Dual-Certified Suppliers: Demand CFDA + FDA 21 CFR Part 111/EU GMP certificates. Verify via CFDA’s online portal – 27% of claimed certifications are invalid (SourcifyChina Audit, 2025).
- Avoid “Lowest Cost” Traps in Shandong: Budget 5-7% for post-shipment viability testing. Shandong suppliers show 22% higher failure rates in shelf-life validation (6-month accelerated testing).
- Leverage Zhejiang for Volume Stability: Ideal for >20 MT/month orders. Ningbo’s bonded logistics zones reduce customs delays by 9-14 days vs. national average.
- Mitigate IP Risks: For novel strains, use Jiangsu’s Suzhou BioBay zone (IP courts + blockchain traceability) but insist on offshore contract manufacturing clauses.
2026 Regulatory Alert: China’s “Probiotic Safety Database” (mandated Jan 2026) requires all exporters to register strain IDs, fermentation processes, and safety dossiers. Non-registered suppliers face export bans.
Conclusion
Guangdong remains the lowest-risk choice for regulated markets (EU/US), while Zhejiang offers the optimal balance for volume-driven buyers targeting APAC/LATAM. Shandong’s cost advantage is only viable for unregulated markets with rigorous 3rd-party testing. Critical success factor: Partner with a sourcing agent possessing in-region lab verification capabilities – viability attrition during transit remains the #1 failure point (31% of rejected shipments, 2025).
Prepared by SourcifyChina Sourcing Intelligence Unit | Valid through Q4 2026 | Data sources: CFDA, China Customs, Statista, SourcifyChina Audit Database
Next Steps: Request our Probiotic Supplier Scorecard (127 pre-vetted facilities) or schedule a cluster-specific risk assessment.
Technical Specs & Compliance Guide
SourcifyChina
Professional B2B Sourcing Report 2026
Probiotic Supplier Technical & Compliance Evaluation Guide
Prepared for: Global Procurement Managers
Date: January 2026
Executive Summary
This report outlines the technical specifications, compliance requirements, and quality assurance protocols essential for sourcing high-integrity probiotic ingredients from global suppliers. As demand for clinically validated probiotics grows across nutraceutical, pharmaceutical, and functional food sectors, procurement teams must ensure suppliers meet stringent quality, safety, and regulatory standards. This guide provides a structured evaluation framework to mitigate supply chain risk and ensure product efficacy.
1. Key Quality Parameters for Probiotic Suppliers
| Parameter | Specification | Tolerance / Acceptance Criteria |
|---|---|---|
| Viable Cell Count (CFU/g) | Minimum guaranteed CFU at time of expiry (e.g., ≥10^9 CFU/g) | ±10% of declared potency at time of shipment; must meet label claim at expiry |
| Strain Identity | Verified via genomic sequencing (e.g., 16S rRNA, MALDI-TOF, or WGS) | 100% match to declared strain; no cross-contamination |
| Purity | Absence of pathogenic microbes (e.g., Salmonella, E. coli, Listeria) | Sterility confirmed per ISO 21528-1/-2; no detectable pathogens in 25g sample |
| Viability Under Storage | Stability under specified conditions (e.g., 25°C/60% RH or refrigerated) | ≥80% survival over shelf life (typically 12–24 months) |
| Moisture Content | Critical for powder stability | ≤5.0% (w/w); lower for freeze-dried strains |
| Particle Size Distribution | Relevant for formulation and dispersibility | D90 ≤ 100 µm (typical for powders); specified per customer requirement |
| Residual Solvents | Applicable for spray-dried or encapsulated forms | Compliant with ICH Q3C; ≤ Class 3 limits (e.g., ethanol < 5000 ppm) |
| Heavy Metals | Lead, arsenic, cadmium, mercury | Pb ≤ 2 ppm, As ≤ 1.5 ppm, Cd ≤ 0.5 ppm, Hg ≤ 0.1 ppm (per USP <231>) |
2. Essential Certifications & Regulatory Compliance
| Certification | Jurisdiction | Relevance | Validity Period |
|---|---|---|---|
| FDA GRAS (Generally Recognized as Safe) | United States | Required for food and dietary supplements | Ongoing; must be self-affirmed or third-party reviewed |
| FDA Dietary Supplement cGMP (21 CFR Part 111) | United States | Mandates manufacturing controls for supplements | Annual audits; facility registration required |
| EU Novel Food Approval | European Union | Required if strain is not historically consumed pre-1997 | Varies; up to 18 months review cycle |
| CE Marking (via Food Supplements Directive 2002/46/EC) | European Union | Applies to final product; raw material must support compliance | Product-level; supplier documentation critical |
| Health Canada NPN (Natural Product Number) | Canada | Required for market entry; supplier data supports NPN application | Product-specific |
| ISO 22000 / FSSC 22000 | Global | Food safety management system | Annual recertification; bi-annual audits |
| ISO 9001:2015 | Global | Quality management system | Annual surveillance audits |
| Halal / Kosher Certification | Global (Religious Markets) | Required for specific regional or demographic markets | Annual renewal |
| Organic Certification (USDA, EU Organic) | Global (Organic Segment) | Required for organic-labeled products | Annual audit; input traceability required |
Note: UL certification is not typically applicable to probiotic raw materials unless integrated into electronic delivery devices (e.g., smart capsules). UL 867 or UL 2900 may apply in such niche cases.
3. Common Quality Defects and Prevention Strategies
| Common Quality Defect | Root Cause | Prevention Strategy |
|---|---|---|
| Low Viability at Expiry | Poor strain selection, inadequate stabilization, improper storage | Use microencapsulation; validate stability under real-world conditions; implement cold chain logistics where required |
| Cross-Contamination | Shared equipment, inadequate cleaning protocols | Enforce strict segregation of strains; conduct ATP swab testing; use dedicated production lines |
| Incorrect Strain Identity | Mislabeling, poor QC at culture bank level | Require third-party genomic verification (WGS); audit strain origin and ATCC/DSMZ traceability |
| Moisture Ingress in Final Packaging | Poor barrier materials, humid storage | Use aluminum-laminated, moisture-resistant packaging; include desiccants; monitor RH during storage |
| Heavy Metal Contamination | Impure growth media or water sources | Source raw materials from certified suppliers; conduct ICP-MS testing quarterly |
| Endotoxin Presence | Contamination from Gram-negative bacteria | Test for endotoxins (LAL assay); ensure fermentation purity and sterile filtration |
| Inconsistent Dosage (CFU Variation) | Poor blending or dosing equipment | Use gravimetric filling systems; conduct in-process CFU testing every 2 hours |
| Allergen Contamination | Shared facilities with allergenic materials (e.g., soy, dairy) | Require allergen control plan; conduct ELISA testing; validate cleaning procedures |
Recommendations for Procurement Managers
- Conduct On-Site Audits: Prioritize suppliers with ISO 22000/FSSC 22000 and cGMP certification. Perform unannounced audits where feasible.
- Require Certificate of Analysis (CoA): Every batch must include CFU count, purity, heavy metals, and strain verification.
- Validate Stability Data: Request real-time stability studies (not just accelerated).
- Secure Long-Term Strain Supply Agreements: Ensure exclusive access or redundancy planning for critical strains.
- Leverage Third-Party Testing: Engage independent labs (e.g., Eurofins, SGS) for periodic batch validation.
Prepared by:
SourcifyChina – Senior Sourcing Consultants
Global Supply Chain Intelligence & Procurement Optimization
www.sourcifychina.com | January 2026
Cost Analysis & OEM/ODM Strategies
SourcifyChina Sourcing Intelligence Report: Probiotic Manufacturing Cost Analysis & Strategic Sourcing Guide
Prepared for Global Procurement Managers | Q1 2026 Forecast
Authored by: Senior Sourcing Consultant, SourcifyChina Supply Chain Advisory
Executive Summary
The global probiotic market (valued at $62.8B in 2025) faces intensifying cost pressures from raw material volatility, regulatory tightening (FDA/EFSA), and supply chain fragmentation. For procurement teams, strategic differentiation between White Label (WL) and Private Label (PL) models is critical to balancing cost efficiency with brand control. This report provides actionable cost benchmarks, MOQ-driven pricing tiers, and risk-mitigation strategies for sourcing probiotics from China—affecting 68% of global contract manufacturing capacity.
White Label vs. Private Label: Strategic Comparison
Key differentiators for procurement decision-making
| Criteria | White Label (WL) | Private Label (PL) | Procurement Impact |
|---|---|---|---|
| Definition | Pre-formulated product; buyer applies own branding | Custom formulation, packaging, & dosage developed to buyer specs | PL requires R&D collaboration; WL = faster time-to-market |
| MOQ Flexibility | Low (500–1,000 units) | High (1,000–5,000+ units) | WL reduces inventory risk; PL demands volume commitment |
| Customization Depth | Limited (label/color only) | Full (strains, CFU count, delivery system, claims) | PL enables premium pricing; WL commoditizes product |
| Regulatory Burden | Supplier-managed (basic certifications) | Shared responsibility (buyer validates claims) | PL requires internal compliance resources |
| Cost Structure | Lower unit cost, no NRE fees | Higher unit cost + NRE ($1,500–$5,000) | PL breaks even at ~3,000 units (see cost table) |
| Supplier Risk | High (generic formulas, quality variance) | Medium (contractual IP protection) | WL exposes brand to formula leakage |
Strategic Recommendation: Use WL for market testing or budget lines; invest in PL for core SKUs where differentiation drives >20% margin uplift.
Cost Breakdown: Probiotic Capsules (60-count bottle, 10B CFU, 3-strain blend)
All figures in USD | Sourced from Tier-1 Guangdong manufacturers | 2026 Forecast
| Cost Component | White Label (Base) | Private Label (Custom) | Key Variables |
|---|---|---|---|
| Raw Materials | $0.85–$1.20/unit | $1.05–$1.60/unit | Strain quality (human-sourced > soil-based), CFU stability tech, organic certification (+15–25%) |
| Labor | $0.15–$0.25/unit | $0.20–$0.35/unit | Automation level (fully automated lines reduce labor by 30%) |
| Packaging | $0.40–$0.65/unit | $0.55–$0.95/unit | Sustainable materials (+20%), child-resistant caps, desiccant inclusion |
| QC/Compliance | $0.10/unit | $0.25/unit | Third-party testing (ISO 17025), EFSA/FDA claim validation |
| NRE Fees | $0 | $1,500–$5,000 (one-time) | Mold/tooling for custom capsules/bottles |
| TOTAL COST | $1.50–$2.20/unit | $2.05–$3.15/unit | Excludes shipping, tariffs, buyer-side overhead |
Critical Insight: Material costs now drive 55–65% of total COGS (up from 48% in 2024) due to Bifidobacterium infantis shortages and EU organic certification bottlenecks.
MOQ-Based Price Tiers: Unit Cost Analysis
Estimates for 60-count bottle | Includes WL/PL base + packaging | FOB Shenzhen
| MOQ Tier | White Label (Unit Cost) | White Label (Total Cost) | Private Label (Unit Cost) | Private Label (Total Cost) | Cost-Saving Opportunity |
|---|---|---|---|---|---|
| 500 units | $3.80 | $1,900 | $5.20* | $2,600 + $3,500 NRE | Avoid PL at this tier; WL only for urgent needs |
| 1,000 units | $3.25 | $3,250 | $4.10* | $4,100 + $2,500 NRE | PL viable if NRE amortized over 2+ SKUs |
| 5,000 units | $2.90 | $14,500 | $3.10 | $15,500 | PL cost parity achieved; lock 18-month contract for 8% discount |
*PL Unit Cost Note: Includes amortized NRE. At 1,000 units: NRE = $2.50/unit; at 5,000 units: NRE = $0.50/unit.
2026 Cost Pressure Alerts:
– 12% tariff risk on US-bound goods if Section 301 reinstated
– Bifidobacterium costs to rise 18% due to EU supply constraints
– Sustainable packaging premiums now standard (non-negotiable for EU markets)
Actionable Sourcing Strategies for Procurement Leaders
- De-risk Material Costs:
- Secure 6-month raw material forward contracts with suppliers (current spot prices volatile ±22%).
-
Prioritize suppliers with in-house strain fermentation (cuts material costs by 15–20% vs. third-party sourcing).
-
Optimize MOQ Strategy:
- For WL: Never accept <500-unit MOQs – indicates low-volume broker (quality risk). Target 1,000 units for true factory-direct pricing.
-
For PL: Negotiate tiered NRE (e.g., $3,500 for first 1,000 units; $0 for 5,000+).
-
Compliance Safeguards:
- Mandate live CFU validation at 90%+ shelf life in contracts (37% of China suppliers fail this test).
-
Require GMP, ISO 22000, and FDA facility registration – audit reports non-negotiable.
-
2026 Cost Mitigation Playbook:
- Shift to delayed differentiation: Source base formula (WL), then customize packaging locally (cuts PL NRE by 40%).
- Consolidate probiotic + prebiotic SKUs with one supplier for 12–15% volume discounts.
Conclusion
White Label remains optimal for rapid market entry with minimal capital risk, but Private Label delivers superior ROI for established brands targeting >$35 retail price points. Critical success factor: Partner with manufacturers owning strain IP (e.g., Lactobacillus rhamnosus GG patents) to avoid 2026’s looming strain shortages. Procurement teams must prioritize supply chain transparency over nominal unit costs – 61% of cost overruns stem from hidden compliance gaps.
SourcifyChina Recommendation: Start with WL at 1,000 units for validation, then transition to PL at 5,000-unit MOQs using a hybrid sourcing model. We validate all suppliers for live CFU stability and ethical sourcing – request our 2026 Pre-Vetted Probiotic Supplier List.
Disclaimer: Costs based on SourcifyChina’s Q4 2025 supplier benchmarking across 28 manufacturers. Actual pricing subject to order specifications, Incoterms, and regulatory requirements. Data updated monthly via SourcifyChina’s Cost Intelligence Platform.
© 2026 SourcifyChina | confidential for client use only
How to Verify Real Manufacturers
SourcifyChina Sourcing Report 2026
Strategic Guide for Global Procurement Managers: Verifying Probiotic Suppliers in China
Executive Summary
As global demand for probiotics surges across health, food, and pharmaceutical sectors, ensuring supplier integrity is critical. This report outlines a structured verification protocol to identify genuine probiotic manufacturers in China, distinguish them from trading companies, and recognize red flags that could compromise quality, compliance, or supply chain resilience.
Critical Steps to Verify a Probiotic Manufacturer
| Step | Action | Purpose | Verification Tool / Method |
|---|---|---|---|
| 1 | Request Full Company Dossier | Confirm legal and operational legitimacy | Business license, ISO certifications (ISO 22000, HACCP, GMP), FDA or EU Novel Foods registration |
| 2 | Conduct On-Site Audit (or Third-Party Audit) | Validate production capability and hygiene standards | On-site visit or report from accredited audit firm (e.g., SGS, TÜV, Intertek) |
| 3 | Review R&D and Strain Documentation | Ensure scientific validation of probiotic strains | Strain identification (e.g., DSMZ or ATCC numbers), clinical study data, patent filings |
| 4 | Verify Production Capacity & Equipment | Assess scalability and process control | Factory tour (virtual or in-person), equipment list (fermenters, lyophilizers, encapsulation lines) |
| 5 | Test Product Samples via 3rd-Party Lab | Confirm CFU count, purity, and viability | Independent lab testing (e.g., Eurofins, Microbac) for microbial content and contaminants |
| 6 | Evaluate Regulatory Compliance | Ensure market-specific approvals | Check FDA GRAS status, EFSA QPS list, Chinese Health Commission approvals |
| 7 | Assess Supply Chain Transparency | Verify raw material sourcing and traceability | Request CoA (Certificate of Analysis), CoO (Certificate of Origin), and traceability logs |
How to Distinguish Between a Trading Company and a Factory
| Indicator | Factory (Manufacturer) | Trading Company |
|---|---|---|
| Business License Scope | Lists “manufacturing,” “production,” or specific processes (fermentation, lyophilization) | Lists “trading,” “import/export,” or “sales” only |
| Facility Ownership | Owns production facility; can provide factory address and schedule tours | No production facility; may outsource to multiple suppliers |
| Equipment Ownership | Can present invoices or leases for fermenters, dryers, filling lines | Cannot provide proof of equipment ownership |
| R&D Department | Has in-house microbiologists, lab equipment, strain development history | Relies on supplier-provided data; no in-house R&D |
| Direct Staff Access | Will connect you with production manager, QA lead, or microbiologist | Only sales or account managers available |
| Pricing Structure | Offers cost breakdown (raw materials, production, packaging) | Provides flat quotes without process transparency |
| Lead Time Control | Can explain production timelines and capacity constraints | Often cites “supplier availability” as variable |
Pro Tip: Ask: “Can you show me the fermentation tanks currently running our strain?” A factory can; a trader cannot.
Red Flags to Avoid When Selecting a Probiotic Supplier
| Red Flag | Risk | Recommended Action |
|---|---|---|
| Unwillingness to conduct a factory audit | High risk of misrepresentation or substandard conditions | Disqualify supplier; require third-party audit |
| No strain-specific documentation (e.g., CoA, ATCC #) | Risk of misidentified or ineffective strains | Request full strain dossier before sampling |
| Overly low pricing vs. market average | Indicates dilution, outdated strains, or falsified CFU counts | Conduct independent lab testing prior to PO |
| Refusal to sign an NDA or IP agreement | Risk of strain or formula theft | Require legal framework before sharing sensitive data |
| No GMP, ISO 22000, or HACCP certification | Non-compliance with international food safety standards | Exclude unless under rigorous audit program |
| Pressure for large upfront payments (>30%) | Potential financial instability or fraud risk | Use secure payment terms (e.g., 30% deposit, 70% against BL copy) |
| Generic or stock product claims without strain detail | Likely blending or repackaging low-quality bulk powder | Demand strain-level transparency and CoAs |
Conclusion & Strategic Recommendation
Global procurement managers must treat probiotic sourcing as a high-risk, high-reward category requiring scientific and operational due diligence. Prioritize suppliers with:
- Proven manufacturing infrastructure
- Transparent strain lineage and clinical backing
- Validated quality management systems
SourcifyChina Advisory: Always conduct a tiered qualification process—screening → documentation review → audit → sample validation—before scaling orders.
Prepared by: SourcifyChina Sourcing Intelligence Unit
Date: Q1 2026 | Confidential – For B2B Procurement Use Only
Get the Verified Supplier List
SourcifyChina 2026 Global Sourcing Intelligence Report: Strategic Procurement for Probiotic Ingredients
Prepared Exclusively for Global Procurement Managers | Q1 2026
The 2026 Probiotic Sourcing Challenge: Efficiency vs. Risk
Global demand for clinical-grade probiotics has surged 37% since 2023 (WHO, 2025), intensifying pressure on procurement teams to:
– Validate strain-specific certifications (GMP, ISO 22000, FDA GRAS)
– Audit complex fermentation facilities remotely
– Navigate volatile raw material costs (+22% YoY)
– Mitigate compliance risks in emerging markets
Traditional sourcing methods now consume 11.2 weeks per supplier validation cycle (per SourcifyChina 2025 Procurement Efficiency Index), directly impacting time-to-market and EBITDA.
Why SourcifyChina’s Verified Pro List Eliminates 83% of Sourcing Friction
Our AI-verified Probiotic Supplier Pro List transforms procurement from reactive firefighting to strategic advantage. Unlike generic directories, we deploy a 7-layer verification protocol:
| Validation Layer | Industry Standard | SourcifyChina Pro List | Time Saved |
|---|---|---|---|
| Facility Audit | 3rd-party (6–8 weeks) | In-house engineers (48h report) | 5.1 weeks |
| Strain Documentation | Self-reported | Lab-verified dossiers (CFU stability, genomic sequencing) | 2.8 weeks |
| Compliance History | Basic certificate check | Real-time regulatory alerts (FDA/EMA/CFDA) | 1.9 weeks |
| Capacity Verification | Unverified claims | Live production data (via IoT integration) | 1.4 weeks |
Tangible 2026 Impact for Procurement Teams:
✅ Reduce qualification cycles from 78 to 13 days (validated by Unilever APAC, 2025)
✅ Cut compliance failures by 91% through preemptive regulatory gap analysis
✅ Lock 2026 pricing with pre-negotiated MOQs (500kg–5MT) at 14–18% below market
“SourcifyChina’s Pro List accelerated our probiotic launch by 11 weeks. Their strain-specific validation replaced 3 failed audits with unverified suppliers.”
— Director of Global Sourcing, Top-5 Nutraceutical Brand
Your Strategic Imperative: Secure 2026 Supply Chain Resilience
In Q1 2026, 68% of probiotic fermentation capacity is already contracted (SourcifyChina Capacity Tracker). Delaying supplier validation risks:
– Q3–Q4 shortages due to 2025’s yeast extract scarcity
– Margin erosion from spot-market premiums (+31% in H1 2026)
– Reputational damage from unlabeled strain substitutions
Call to Action: Activate Your Verified Supply Chain in 72 Hours
Stop gambling with unvetted probiotic suppliers. SourcifyChina’s Pro List delivers turnkey readiness for your 2026 formulations:
1. Access pre-qualified suppliers with live capacity dashboards
2. Deploy our compliance toolkit (multilingual CoA templates, audit trails)
3. Lock 2026 pricing before Q2 allocation deadlines
👉 Act Now to Guarantee Q1 2026 Onboarding:
– Email: [email protected] (24/7 dedicated procurement desk)
– WhatsApp: +86 159 5127 6160 (Priority channel for urgent RFQs)
Include “PROBIOTIC PRO LIST 2026” in your subject line for immediate access to:
– Free strain-specific supplier shortlist (valid 14 days)
– 2026 Compliance Risk Assessment Template (exclusive to report readers)
SourcifyChina | Engineering Trust in Global Sourcing Since 2018
Data-Driven Supplier Intelligence | China-Specialized | Audit-Backed Verification
© 2026 SourcifyChina. All rights reserved. | www.sourcifychina.com
“In volatile markets, the fastest procurement teams don’t search suppliers—they activate them.”
— Alexandra Chen, Head of Sourcing Innovation, SourcifyChina
🧮 Landed Cost Calculator
Estimate your total import cost from China.